FindTrial
Sign In

PD-L1/IDO peptide vaccine

BIOLOGICAL2 trials

Sponsors

Inge Marie Svane, University of California, Davis

Conditions

High Risk Non-Muscle Invasive Bladder Urothelial CarcinomaMetastatic MelanomaStage 0a Bladder Cancer AJCC v8Stage 0is Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8

Phase 1

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
CompletedNCT03047928
Inge Marie SvaneMetastatic Melanoma
Start: 2018-02-22End: 2022-12-31Updated: 2025-02-20
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Active, not recruitingNCT05843448
University of California, DavisHigh Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 +1
Start: 2023-04-19End: 2026-12-01Updated: 2026-07-16

Related Papers

Five-year clinical outcome and immune biomarkers of durable response from the MM1636 trial on IDO/PD-L1 vaccination and PD-1 blockade in first line metastatic melanoma.
2025-12-14
A phase 1 study of IO102-IO103 vaccine plus pembrolizumab in patients with BCG-intolerant or unresponsive non-muscle invasive bladder cancer (NMIBC).
Journal of Clinical Oncology2024-01-29
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Journal for ImmunoTherapy of Cancer2023-05-0131 citations
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
Frontiers in Immunology2022-10-1745 citations
Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab
Cancer Research2022-06-151 citations
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
Journal of Clinical Oncology2022-06-014 citations
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
2021-12-09148 citations
Durable Clinical Responses and Long-Term Follow-Up of Stage III–IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study—A Brief Research Report
Frontiers in Immunology2018-09-1947 citations